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Abstract: Background: The inci-
dence of hypertension in the pedi-
atric population has been increas-
ing. Childhood blood pressure is
predictive of adult BP. The renin
angiotensin aldosterone system
pathway is important in the me-
diation of pediatric hypertension.
New therapies approved  for
adults   are  often  used  off  label
in  children  with  little  or  no
efficacy  and  safety  data  in the
paediatric  population The angio-
tensin receptor blockers has been
shown to be effective and  safe in
the treatment of pediatric hyper-
tension.
Objective: The   objective  of  this
review is to highlight available
clinical evidence  on  the efficacy,
safety tolerability and kinetics of
angiotensin  receptor blockers  in
childhood hypertension and its
antiproteinuric effect in renal
disease.
Method: The search strategy was
based on Pubmed, Medline data-
base, Cochrane Library, manual,
Google and Yahoo searches. We
summarized ten  randomized con-
trolled trials (RCTs  .The  search
was done in June 2014  and  up-
dated  in January and May  2015
in English  language .
Results: A  total  of   120  publica-
tions  were  accessed  from  which
68  references were included  in
the  review. The design and out-
come of ten key randomised trials
are summarised. Randomised trials
have demonstrated the efficacy of
angiotensin receptor blockers in
the pediatric population aged 1–16
years. This  class  of  drugs  reduce
blood  pressures in  pediatric pa-
tients with  hypertension and   pro-
teinuria in renal  disease. Safety
pharmacokinetic, dosage, and
palatability  of  adult formulations
for  the  paediatric  age  group  are
highlighted
Conclusion: Angiotensin receptor
antagonists are useful effective
and  safe  alternatives  to available
antihypertensive therapy in paedi-
atric  population. Angiotensin re-
ceptor antagonists should however
be prescribed cautiously for sexu-
ally active adolescent females due
to concern about angiotensin
receptor blocker fetopathy.
Keywords: Angiotensin  receptor
blockers, childhood hypertension,
drug safety, drug efficacy, pharma-
cokinetics  and renal diseases.
Introduction
Hypertension is a common disease in adults, with a
prevalence which increases with age, ranging from 15%
in young adults to 60% in persons over the age of 65
years1. Persistent  hypertension in children  is   predomi-
nantly  secondary  and  norms for blood pressure in chil-
dren and adolescents, definitions of hypertension ,
guidelines for the diagnosis  and treatment of hyperten-
sion have been   published for children aged 2 to 18
years2.
Globally the prevalence of hypertension in children is on
the increase3 and varies between studies a study in
South East Nigeria reported  the prevalence of hyperten-
sion in adolescents to be 4% with male and female
prevalence rates of 3.8% and 6.9% respectively4. Chil-
dren with elevated blood pressure tend to maintain that
level of blood pressure into adulthood5.
Normal blood pressure values, definition of  hyperten-
sion
In the criteria of the Fourth Report on the Diagnosis,
Evaluation, and Treatment of High Blood Pressure in
Children and Adolescents, normal BP in children is de-
fined as  systolic  blood  pressure  (SBP) and  diastolic
blood  pressure (DBP) less than 90th percentile for age,
sex and height, whereas hypertension is defined as SBP
and/or DBP persistently 95th percentile or more, meas-
ured on at least three separate occasions with the auscul-
tatory method2.
The fourth report also provides criteria for staging the
severity of hypertension in children and adolescents, and
this  is  useful  clinically to guide evaluation and man-
agement(Table1) 2
Table 1: Definition and classification of hypertension in  chil-
dren and adolescents
Modified from task force on high blood pressure in children &
adolescents2.
The renin-angiotensin-aldosterone system (RAAS)
The renin-angiotensin-aldosterone system (RAAS)
plays an important role in the pathogenesis of hyperten-
sion in patients of all ages. Angiotensin II, the principal
pressor  agent of RAAS  mediates   the   effects  of an
over-active renin-angiotension system  such  as vaso-
constriction and retention of  sodium and water  which
leads to hypertension6,7. Plasma concentrations of an-
giotensin II and aldosterone are largely determined by
the level of  plasma  rennin activity8.  Renin is secreted
by the  juxtaglomerular apparatus  in response to  vari-
ous stimuli such as  a  decrease in arterial blood pressure
as detected by  barareceptors  a decrease in sodium lev-
els in the ultrfiltrate of the nephron,   and  lastly sympa-
thetic  nervous system activity, which also controls
blood pressure, acting through the beta1 adrenergic re-
ceptors.9
The  angiotensin   receptors  are  a  class  of G protein
coupled receptors with angiotensin II as  their  ligand10.
The receptors are responsible for the signal transduction
of  the  vasoconstricting   effect  of  angiotensin II. 11
Angiotensin II  is  a  very  important  mediator  of  pro-
gressive renal  failure. It is responsible  for  proteinuria
which  results  from  glomerular hyperfiltration due to
increased intraglomerular pressure and  structural
changes  to  the  glomeruli caused  by  proinflamatory
mediators, fibroblast  proliferation   and  production of
superoxide free radicals.12
Angiotensin  II  antagonists  exerts  their  blood  pres-
sure  lowering effects by directly  and  selectively
blocking  the activity  of  angiotensin  II  on the AT 1
receptor.Angiotensin-II antagonists  have been shown to
be both well tolerated and effective in lowering blood
pressure  in  adult  clinical trials.10
Justification  for this   review
New medicines can result in significant improvements
in reducing morbidity and mortality13. Drugs approved
for  adults  are  often  used  in  children   because  lim-
ited pediatric clinical trials, has led to limited or no pedi-
atric documentation with respect to many drugs ap-
proved for  adults  . This off label  use  of  drugs  in chil-
dren  often  implies  that  the  dose, dosing frequency, or
the age/weight of the patient is  not in agreement with
Class SBP and/or DBP Percentile
Normal <90th
High-normal > 90th to < 95th
> 120/80 even if below 90th percentile in
adolescents
Stage1 hypertension 95th percentile to the 99th percentile plus
5mmHg
Stage2 hypertension > 99th percentile plus 5mmHg
drug labeling and   includes  where a total lack of infor-
mation in the label about pediatric use of the drug and
the use of a non-approved dose in relation to age or
weight.14-17 Concerns has been expressed by different
authors about the interpretation of safety data by the
pharmaceutical industry in relation to new products. 18,19
This  is  because  many physiologic differences between
children and adults may result in age-related changes in
pharmacokinetics and pharmacodynamics  of  drugs.
20,21Therefore  adjusting   from adult dosages does not
always give correct  doses  for  children .
Reports  have  highlighted   safety concerns regarding
the use of angiotensin II receptor blockers in preschool
children. Although   considered  to  be  unrelated to the
investigational drug these reports highlighted the deaths
of three preschool children out of the 183 children with
hypertension who received valsartan or candesartan in
two clinical trials. 22
The primary objective of this review  was to highlight
available clinical evidence on the efficacy, safety toler-
ability  and kinetics of angiotensin  receptor blockers  in
childhood  hypertension and  its  antiproteinuric effect
in  renal  disease .
Methods
The search strategy was based on Pubmed, Medline da-
tabase, Cochrane Library,  manual,  Google  and   Ya-
hoo searches. The search was done  in English  language
in June 2014  and  updated  in January  and  may  2015.
There was no limitation to the year of publication.
Search   was based on the following   keywords : angio-
tensin receptor blockers, childhood hypertension, drug
safety, drug efficacy kinetics, tolerability, renal diseases.
randomised clinical trials in pediatric patients with  hy-
pertension, and safety of antihypertensive drugs in
pregnancy .
Results
A  total  of   120  publications  were  accessed  from
which  68  references were included  in the  review .
Ten  key  randomised trials  are summarised and pre-
sented  in  table   2. Randomised  trials   have demon-
strated the efficacy  of angiotensin  receptor  blockers  in
the pediatric population aged 1–16 years. This  class  of
drugs reduce blood  pressures in pediatric  patients  with
hypertension and proteinuria in renal  disease. Safety
pharmacokinetic, dosage,  issues  of  paediatric  formu-
lations  and palatability  for  the  child  have  been  high-
lighted
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Table  2: Study  design  and  treatment outcome of   studies conducted  with arbs    in  children
Study Deisign Outcome /Conclusion
Lubrano,R et al. 40
Pediatrics 2006;118;e833;
A randomized study  of 10 children (mean
age: 12.3 _ 4.06 years) with proteinuria
resulting from chronic renal diseases of
various causes.
In the short term, the combination of
angiotensin-converting enzyme in-
hibitors and angiotensin II type 1
receptor antagonists for children with
proteinuria of renal origin reduced
proteinuria significantly
Meier, CM et al. 63
BrJClinPharmacol. 2007 ; 63(5): 628–
631.
Taste and smell acceptability of five angio-
tensin II receptor blockers were compared
among 21 nephropathic children using a
visual analogue scale palatability score.
From the perspective of the neph-
ropathic child, the taste of pulverized
candesartan cilexetil is superior to
that of irbesartan,losartan, telmisartan
or valsartan




This was a multicenter  double-blind, ran-
domized, multicenter study
performed at 36 centers
In children _6 years of age, valsartan
effectively lowered SBP and diastolic
blood pressure compared with pla-
cebo. Valsartan treatment had no
demonstrable negative effects on
growth and development
.
Hazan, L et al. 35
Hypertension.
2010;55:1323-1330.
A  randomized, multicenter, double-blind,
parallel-group,
prospective dose-ranging study in patients 6
to 16 years of age with primary or secon-
dary hypertension
Olmesartan medoxomil was safe and
efficacious in children with hyperten-
sion, resulting in significant blood
pressure reductions.
Webb NJ et al.39
Clin J Am Soc
Nephro l2010. 5: 417–424,
12-week, double-blind, multinational study Losartan significantly lowered pro-
teinuria and was well tolerated after
12 weeks in children aged 1 to 17
years with proteinuria with or without
hypertension.
Wells, T.  et al. 31
J Clinhypertens2011 ;13(5):357-65.
Children  aged 6 to 16 years old with a
mean sitting systolic BP (SSBP) _95th
percentile for age, sex, and height  with
documented hypertension  were studied in a
prospective 4-week,double-blind, random-
ized,multicenter  study
Valsartan appeared to provide dose-
dependent reductions in SSBP and
SDBP in children with hypertension
over a dose range of 0.1 mg⁄ kg to 4.6
mg⁄ kg (10 mg–160 mg).
Schaefer et al33
J Hypertens 29:000–000  2011
A 12-week, randomized, double-blind,
parallel-group, active-controlled study
Valsartan and enalapril provided
comparable BP reductions and effec-
tive BP control and were well toler-
ated in hypertensive children aged 6–
17 years.
Wells  TG et al 55
Paediatr  Drugs
2012  1;14(6):401-9.
An open-label, multicenter, single-dose
study was conducted in children and ado-
lescents aged 12 months-16 years with
hypertension
Olmesartan medoxomil was well
tolerated and demonstrated a pharma-
cokinetic profile in pediatric patients
similar to that of adults when adjusted
for body size
Moretti, ME. et al 44
Obstetrics and Gynecology International
Volume 2012,
a prospective, observational, controlled
cohort
study.
inadvertent exposure to ACE inhibi-
tors/ARBs in the first trimester of
pregnancy may not present significant
risks for malformations in live births
but may be associated with higher
rates of spontaneous abortion.
Schaefera, F et al34
J Hypertens2013  31:993–1000
I A   multicenter, randomized, double-
blind,parallel-group study, 75 patients with
a documented history of hypertension
In a  dose  dependent   manner.
Valsartan demonstrated significant
reductions in BP compared with base-
line and provided consistent reduc-
tions over26 weeks.
Discussion
Currently, multiple antihypertensive agents are approved
for use in children23. Data   on the  use  of  renin   angio-
tensin system antagonists  in the  treatment  of  child-
hood  hypertension are available24-29. This review high-
lights the efficacy, safety  tolerability  and kinetics   of
angiotensin  receptor blockers  in  childhood  hyperten-
sion and  its  antiproteinuric effect  in  renal  disease .
Efficacy
Two recent trials have demonstrated the efficacy of
angiotensin receptor  blocker monotherapy in the pediat-
ric population aged 1–16 years. Once-daily oral prepara-
tions of valsartan achieve adequate blood pressure con
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trol in the pediatric population30. In  children and adoles-
cents aged 6-16 years  significant dose-dependent reduc-
tions from baseline in mean sitting systolic BP (msSBP)
were observed for recipients of valsartan following 2
weeks' treatment31. Compared  to enalapril  in hyperten-
sive children and adolescents aged 6-17 years, valsartan
was no less effective than enalapril in reducing BP. Fol-
lowing 12 weeks' treatment, the least square mean re-
duction from baseline in mean  systolic  blood   pressure
in recipients of valsartan was non-inferior to that in re-
cipients of enalapril and  was well  tolerated32,33.
In a multicenter, randomized, double-blind, parallel-
group study, 75 patients with a documented history of
hypertension were randomized to receive valsartan
(0.25, 1 or 4 mg/kg per day) for 6 weeks, then reran-
domized to receive placebo or valsartan for 2 weeks.  At
Week 6, significant reductions in MSSBP (P<0.05) from
baseline were observed for all three valsartan doses34.
The efficacy and safety of olmesartan medoxomil in
children with hypertension, defined as systolic blood
pressure measured at or above the 95th percentile (90th
percentile for patients with diabetes, glomerular kidney
disease, or family history of hypertension) for age, gen-
der, and height while off any antihypertensive medica-
tion current was   investigated.  Efficacy results showed
a dose-dependent, statistically significant reduction in
seated trough systolic and diastolic blood pressure. The
olmesartan medoxomil dose response remained statisti-
cally significant when adjusted for body weight. Olme-
sartan medoxomil was safe and efficacious in children
with hypertension, resulting in significant blood pres-
sure reductions35.
Regardless of underlying aetiology, the presence of hy-
pertension is associated with cardiovascular morbidity
and progressive kidney injury36.   In the  Chronic Kidney
Disease in Children study, 37% of children with chronic
kidney disease were diagnosed with elevated BP, and
yet 39% of these were not receiving antihypertensive
medication37.
The use of Angiotensin II receptor blockers is largely
established in adult   patients with kidney disease be-
cause, like converting enzyme inhibitors, they are more
effective than most other antihypertensive drugs in
slowing the progression towards end-stage kidney dis-
ease38.
A subgroup analysis of a 12-week, double-blind study
demonstrated that losartan significantly lowered protein-
uria versus placebo and amlodipine and was well toler-
ated in children (1-17 years old) with proteinuria secon-
dary to Alport syndrome. Losartan maintained proteinu-
ria reduction, and enalapril produced  a  further protein-
uria reduction over the 3-year study period. Both agents
were generally well tolerated. .ARAs can be considered
effective and safe in lowering BP and proteinuria in the
pediatric age group39.
A study enrolled 10 children (mean age: 12.3 _ 4.06
years) with proteinuria resulting from chronic renal dis-
eases of various causes and   investigated whether the
combination of an angiotensin-converting enzyme in-
hibitor and an angiotensin II type 1 receptor antagonist
offers better control of proteinuria and cardiovascular
parameters without causing adverse side effects.  In the
short term, the combination of angiotensin-converting
enzyme inhibitors and angiotensin II type 1 receptor
antagonists for children with proteinuria of renal origin
reduced proteinuria significantly, compared with base-
line or either drug alone. Furthermore, echocardio-
graphic studies gave evidence of reduction of left ven-
tricular hypertrophy. Additional studies will    evaluate
long-term results40.
Safety and tolerability
There are very few data on the safety of antihypertensive
drugs in pregnancy .41 Generally  the class of angio-
tensin II receptor blockers   (ARBs) has proved to be
better tolerated than other leading classes of antihyper-
tensive agents42,43.
Exposure to angiotensin II receptor blockers during the
second part of pregnancy can lead to reduced fetal kid-
ney perfusion that may result in oligoamnios  and neo-
natal renal insufficiency, and  these are  similar to  ab-
normalities observed after exposure to angiotensin-
converting enzyme inhibitors44, Intrauterine growth re-
striction, prematurity, patent ductus arteriosus, severe
neonatal hypotension, neonatal anuria, and neonatal or
fetal death have also been observed with these drugs .
Anuria associated with oligohydramnios may produce
fetal limb contractures, craniofacial deformities,and pul-
monary hypoplasia45,46.
Although   published cohort studies and series 41,44,46-50
showed different  malformation rates after first trimester
exposure to ACE inhibitors/ARBs,  angiotensin II recep-
tor blockers should  be avoided in  pregnancy.  However
if these agents are prescribed accidentally to a pregnant
woman, monitoring of amniotic fluid volume and beta2-
microglobulin fetal blood levels after discontinuation of
the AT1 antagonist can provide critical data for advising
parents on pregnancy and fetal outcome43. In  a  study
there  were no differences in rates of major malforma-
tions. Both the ACE-ARBs and disease-matched groups
exhibited significantly lower birth weight and gesta-
tional ages than the healthy controls (P <0.001 for both
variables). There was a significantly higher rate of mis-
carriage noted in the ACE/ARB group (P <0.001).
These results suggest that ACE inhibitors/ARBs are not
major human teratogens; however, they may be associ-
ated with an increased risk for miscarriage 45.
A  trial of angiotensin II receptor blockers (ARBs)   was
performed in children 0-5 years of age. Three deaths
occurred in the 183 (1.6%) hypertensive children partici-
pating in the two trials.   At least two of these deaths
occurred in children known to be susceptible to drugs
acting on the renin-angiotensin system, that is, children
with ongoing nephrotic syndrome and acute gastroen-
teritis. Clinicians who prescribe ARBs in preschool chil-
dren need to be aware of the risk of drug toxicity espe-
cially in children susceptible to intravascular dehydra-
tion. Clinicians should consider discontinuing the drugs
in the presence of acute diarrhoea51.
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The efficacy and safety of valsartan were studied in 90
children (mean age: 3.2 years; 60% male; 30% black)
with systolic blood pressure (SBP) _95th percentile.
Nineteen percent received valsartan in addition to previ-
ous antihypertensive therapy. Adverse events were mi-
nor and  serious adverse events and drug-related adverse
events occurred infrequently .Valsartan treatment had no
demonstrable negative effects on growth and develop-
ment. 52
The  safety of valsartan were studied in 90 children
(mean age: 3.2 years; 60% male; 30% black) with sys-
tolic blood pressure (SBP) ≥95 th percentile. Adverse
events were minor and occurred at similar frequencies in
both the valsartan and placebo arms . All of the valsartan
doses evaluated in studies   were well tolerated. The
majority of adverse  events   were mild or moderate and
transient in nature, the most frequent being cough, fever,
upper respiratory infection, and diarrhea  and  are  simi-
lar  to findings    in other clinical trials of antihyperten-
sive medications conducted in older children53,54
Pharmacokinetics
An open-label, multicenter, single-dose study  character-
ized the pharmacokinetics and short-term safety of
olmesartan medoxomil in children and adolescents aged
12 months-16 years with hypertension. Olmesartan me-
doxomil was well tolerated and demonstrated a pharma-
cokinetic profile in pediatric patients similar to that of
adults when adjusted for body size55. Losartan  unlike
valsartan  ,  requires oxidative transformation to the ac-
tive compound . 56 In children, plasma valsartan levels
peak at two hours after oral administration and subse-
quently reduce in a biexponential manner. 57 The plasma
half-life is about four hours in children under six years
of age. In children aged 6–12 years, the plasma half-life
is about five hours. 57 Clearance is not significantly
affected by age after correcting for fat free body mass.
The rate of clearance is 0.076–0.098 L/hour/kg in chil-
dren aged 1–16 years. No significant dosage adjustment
is needed in mild to moderate kidney or liver disease.
56,57
Dosage and palatability
Currently available data indicate that extrapolating adult
doses of the angiotensin antagonists, valsartan58, irbesar-
tan59, losartan60 and,  candesartan 61 is safe and effective
in treating children with arterial hypertension or protein-
uria.
A dose response study in children aged 6–16 years dem-
onstrated that valsartan was efficacious and well toler-
ated in doses ranging from 10 to 160mg
( 0.1–4.6 mg/kg)31,52.  The recommended dosage of val-
sartan for treating hypertension in the pediatric popula-
tion is 1.3–2.7 mg/kg, with a starting dose of 1.3 mg/
kg62. This amounts to a starting dose of 40 mg in chil-
dren below 35 kg and 20 mg for children below 15 kg.
Doses 160 mg (4.7 mg/kg) have not been tested in chil-
dren and may not be recommended44.
In another   study  patients aged <6 years  received an
oral suspension of olmesartan medoxomil at a dose of
0.3 mg/kg of bodyweight (not to exceed 20 mg), those
aged ≥6 years who weighed ≥35 kg received olmesartan
medoxomil 40 mg tablets, and those who weighed <35 
kg received olmesartan medoxomil 20 mg tablets. 55
Lack  of  paediatric  formulations   such as  suspensions
or other age-appropriate drug formulations for drugs
originally designed for use in adults, is a  major  barrier
to the  use  of   angiotensin antagonists in drug therapy
of hypertension in children  and  palatability of  the
medication is crucial for adherence to prescribed drug
regimen63. From the perspective of the child with kidney
disease, the taste of pulverized candesartan  measured
by means of a visual analogue scale  the palatability
score. Is significantly superior to that of pulverized irbe-
sartan, losartan, telmisartan or valsartan63. Tablets  are
crushed  by  parents and  administered   mixed with
solid food or a palatable drink64,65. An extemporane-
ously formulated solution  of  valsartan can be prepared
for children who are unable to swallow commercially
available tablets52
Generally angiotensin receptor blockers can  be  used
as monotherapy or as fixed dose combinations66. The
combination of a diuretic and an  angiotensin receptor
blocker  works well because diuretics induce reflex acti-
vation of  the  renin angiotensin system  potentiating the
action of renin angiotensin system  blockers. The combi-
nation of a renin angiotensin system  blocker and a cal-
cium channel blocker (CCB) has also been widely used
in adults and these agents also have complementary ac-
tions. 67,68
Conclusion
Angiotensin II receptor blockers  selectively   block  the
angiotensin type I receptor. Given its effects on angio-
tensin blockade, angiotensin II receptor blockers   re-
duce blood  pressure  in hypertension  and   proteinuria
in  kidney disease. For these reasons,  and  good   safety
and  tolerability profile,  angiotensin II receptor blockers
are  an attractive drug for use in  children with hyperten-
sion. However angiotensin receptor  antagonists   should
be prescribed cautiously for sexually active adolescent
females due to concern about angiotensin receptor
blocker fetopathy.
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